Transthyretin Binding Heterogeneity and Anti-amyloidogenic Activity of Natural Polyphenols and Their Metabolites*

Transthyretin (TTR) is an amyloidogenic protein, the amyloidogenic potential of which is enhanced by a number of specific point mutations. The ability to inhibit TTR fibrillogenesis is known for several classes of compounds, including natural polyphenols, which protect the native state of TTR by specifically interacting with its thyroxine binding sites. Comparative analyses of the interaction and of the ability to protect the TTR native state for polyphenols, both stilbenoids and flavonoids, and some of their main metabolites have been carried out. A main finding of this investigation was the highly preferential binding of resveratrol and thyroxine, both characterized by negative binding cooperativity, to distinct sites in TTR, consistent with the data of x-ray analysis of TTR in complex with both ligands. Although revealing the ability of the two thyroxine binding sites of TTR to discriminate between different ligands, this feature has allowed us to evaluate the interactions of polyphenols with both resveratrol and thyroxine preferential binding sites, by using resveratrol and radiolabeled T4 as probes. Among flavonoids, genistein and apigenin were able to effectively displace resveratrol from its preferential binding site, whereas genistein also showed the ability to interact, albeit weakly, with the preferential thyroxine binding site. Several glucuronidated polyphenol metabolites did not exhibit significant competition for resveratrol and thyroxine preferential binding sites and lacked the ability to stabilize TTR. However, resveratrol-3-O-sulfate was able to significantly protect the protein native state. A rationale for the in vitro properties found for polyphenol metabolites was provided by x-ray analysis of their complexes with TTR.

[1]  F. Zonta,et al.  Structural evidence for asymmetric ligand binding to transthyretin. , 2015, Acta crystallographica. Section D, Biological crystallography.

[2]  G. Merlini,et al.  An overview of drugs currently under investigation for the treatment of transthyretin-related hereditary amyloidosis , 2014, Expert opinion on investigational drugs.

[3]  E. Nordh,et al.  Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. , 2013, JAMA.

[4]  Teresa Coelho,et al.  Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy , 2013, Journal of Neurology.

[5]  Giuseppe Zanotti,et al.  Structural evidence for native state stabilization of a conformationally labile amyloidogenic transthyretin variant by fibrillogenesis inhibitors , 2013, FEBS letters.

[6]  J. Bieschke Natural Compounds May Open New Routes to Treatment of Amyloid Diseases , 2013, Neurotherapeutics.

[7]  A. Rodriguez-Mateos,et al.  Dietary (poly)phenolics in human health: structures, bioavailability, and evidence of protective effects against chronic diseases. , 2013, Antioxidants & redox signaling.

[8]  Jiang-Ning Zhou,et al.  The binding of resveratrol to monomer and fibril amyloid beta , 2012, Neurochemistry International.

[9]  I. Polikarpov,et al.  Flavonoid interactions with human transthyretin: combined structural and thermodynamic analysis. , 2012, Journal of structural biology.

[10]  K. Ono,et al.  Anti-amyloidogenic effects of soybean isoflavones in vitro: Fluorescence spectroscopy demonstrating direct binding to Aβ monomers, oligomers and fibrils. , 2012, Biochimica et biophysica acta.

[11]  M. Bucciantini,et al.  Aβ(1-42) aggregates into non-toxic amyloid assemblies in the presence of the natural polyphenol oleuropein aglycon. , 2011, Current Alzheimer research.

[12]  C. Robinson,et al.  Trapping of palindromic ligands within native transthyretin prevents amyloid formation , 2010, Proceedings of the National Academy of Sciences.

[13]  P. Butler,et al.  The effect of curcumin on human islet amyloid polypeptide misfolding and toxicity , 2010, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[14]  J. Kelly,et al.  Conformational differences between the wild type and V30M mutant transthyretin modulate its binding to genistein: implications to tetramer stability and ligand-binding. , 2010, Journal of structural biology.

[15]  D. Ehrnhoefer,et al.  EGCG remodels mature α-synuclein and amyloid-β fibrils and reduces cellular toxicity , 2010, Proceedings of the National Academy of Sciences.

[16]  P. Emsley,et al.  Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.

[17]  Steven M. Johnson,et al.  Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses. , 2010, Current opinion in structural biology.

[18]  R. Pullakhandam,et al.  Binding and stabilization of transthyretin by curcumin. , 2009, Archives of biochemistry and biophysics.

[19]  J. Kelly,et al.  Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: the relationship between stability and amyloidosis. , 2008, Biochemistry.

[20]  M. Benson,et al.  The molecular biology and clinical features of amyloid neuropathy , 2007, Muscle & nerve.

[21]  L. Cendron,et al.  Acidic pH-induced conformational changes in amyloidogenic mutant transthyretin. , 2007, Journal of molecular biology.

[22]  J. Köhrle,et al.  Genistein and other soya isoflavones are potent ligands for transthyretin in serum and cerebrospinal fluid. , 2006, The British journal of nutrition.

[23]  J. Kelly,et al.  Genistein, a natural product from soy, is a potent inhibitor of transthyretin amyloidosis. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Steven M. Johnson,et al.  Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. , 2005, Accounts of chemical research.

[25]  Fusheng Yang,et al.  Curcumin Inhibits Formation of Amyloid β Oligomers and Fibrils, Binds Plaques, and Reduces Amyloid in Vivo* , 2005, Journal of Biological Chemistry.

[26]  A. W. Schüttelkopf,et al.  PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. , 2004, Acta crystallographica. Section D, Biological crystallography.

[27]  J. Kelly,et al.  Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants , 2004, Laboratory Investigation.

[28]  Joleen T White,et al.  D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis? , 2003, Biochemistry.

[29]  J. Kelly,et al.  Hydration and packing are crucial to amyloidogenesis as revealed by pressure studies on transthyretin variants that either protect or worsen amyloid disease. , 2003, Journal of molecular biology.

[30]  V. Shnyrov,et al.  Comparative calorimetric study of non-amyloidogenic and amyloidogenic variants of the homotetrameric protein transthyretin. , 2000, Biophysical chemistry.

[31]  A. Olofsson,et al.  A comparative analysis of 23 structures of the amyloidogenic protein transthyretin. , 2000, Journal of molecular biology.

[32]  James C. Sacchettini,et al.  Rational design of potent human transthyretin amyloid disease inhibitors , 2000, Nature Structural Biology.

[33]  A. Wojtczak,et al.  Structures of human transthyretin complexed with thyroxine at 2.0 A resolution and 3',5'-dinitro-N-acetyl-L-thyronine at 2.2 A resolution. , 1996, Acta crystallographica. Section D, Biological crystallography.

[34]  J. Kelly,et al.  Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease. , 1995, Biochemistry.

[35]  A Coda,et al.  Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein. , 1995, Science.

[36]  J. Kelly,et al.  Transthyretin mutation Leu-55-Pro significantly alters tetramer stability and increases amyloidogenicity. , 1993, Biochemistry.

[37]  K. Sletten,et al.  Fibril in senile systemic amyloidosis is derived from normal transthyretin. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[38]  R. N. Ferguson,et al.  Negative cooperativity in the binding of thyroxine to human serum prealbumin. Preparation of tritium-labeled 8-anilino-1-naphthalenesulfonic acid. , 1975, Biochemistry.

[39]  Wolfgang Kabsch,et al.  Integration, scaling, space-group assignment and post-refinement , 2010, Acta crystallographica. Section D, Biological crystallography.

[40]  Vincent B. Chen,et al.  PHENIX: a comprehensive Python-based system for macromolecular structure solution , 2010, Acta crystallographica. Section D, Biological crystallography.

[41]  P. Evans,et al.  Scaling and assessment of data quality. , 2006, Acta crystallographica. Section D, Biological crystallography.